Dosage of Clarithromycin and Amoxicillin
For standard treatment regimens, clarithromycin is dosed at 500 mg twice daily (or extended-release 1,000 mg once daily), and amoxicillin is dosed at 1,000 mg twice daily. 1, 2
Standard Dosing for Various Indications
Helicobacter pylori Infection Treatment
Standard Triple Therapy:
Sequential Therapy (for areas with high clarithromycin resistance):
- First 5 days: PPI standard dose twice daily + Amoxicillin 1,000 mg twice daily
- Next 5 days: PPI standard dose twice daily + Clarithromycin 500 mg twice daily + Metronidazole 500 mg twice daily 1
Community-Acquired Pneumonia
For healthy outpatients:
For outpatients with comorbidities (combination therapy):
Nontuberculous Mycobacterial Diseases
For nodular/bronchiectatic disease (intermittent therapy):
- Clarithromycin 1,000 mg three times weekly 1
For fibrocavitary or severe disease (daily therapy):
Special Dosing Considerations
Renal Impairment
- For amoxicillin in severe renal impairment: 2
- GFR 10-30 mL/min: 500 mg or 250 mg every 12 hours
- GFR <10 mL/min: 500 mg or 250 mg every 24 hours
- Patients with GFR <30 mL/min should NOT receive the 875 mg dose
Pediatric Dosing
- Amoxicillin for pediatric patients >3 months: 20-45 mg/kg/day in divided doses every 8-12 hours 2
- Amoxicillin for infants ≤3 months: Maximum 30 mg/kg/day divided every 12 hours 2
Administration Tips
- Amoxicillin should be taken at the start of a meal to minimize gastrointestinal intolerance 2
- Clarithromycin immediate-release may need to be split into twice-daily dosing due to gastrointestinal intolerance 1, 3
- Clarithromycin extended-release formulation (1,000 mg once daily) may improve compliance and gastrointestinal tolerability compared to immediate-release formulation 3
Common Pitfalls and Caveats
- For H. pylori treatment, standard triple therapy should be started after 72-96 hours of intravenous PPI administration in patients with bleeding peptic ulcer 1
- Clarithromycin can increase concentrations of drugs metabolized by CYP3A, which may be clinically significant for medications with narrow therapeutic indices 4
- For patients with nodular/bronchiectatic MAC disease, gradual introduction of medications (one at a time at 1-2 week intervals) may improve tolerance 1
- Clarithromycin has an active metabolite (14-hydroxyclarithromycin) which contributes to its antimicrobial activity, particularly against H. influenzae 4, 5